Drugs / Afimoxifene
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04009044 | Feb 2020 → Jan 2026 overdue | ductal breast carcinoma in situ, invasive breast carcinoma | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03063619 | Jan 2018 → Oct 2021 | benign mammary dysplasia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02993159 | May 2017 → Mar 2021 | ductal breast carcinoma in situ, estrogen-receptor positive breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00952731 | Dec 2009 → Sep 2011 | ductal breast carcinoma in situ, estrogen-receptor positive breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00272714 | Mar 2003 → Mar 2004 | breast disorder | ASCEND Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afimoxifene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04009044 ↗ |
| Action | Inhibit | “Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.” NCT02993159 ↗ |
| Modality | Other / unclassified | “Hormone therapy” NCT03063619 ↗ |
| Route | Topical | “2mg/breast applied daily in the form of a gel for 4-10 weeks.” NCT00952731 ↗ |